AGEs Polyclonal Antibody

$Paraformaldehyde-fixed, paraffin embedded rat kidney; Antigen retrieval by boiling in sodium citrate buffer (pH6) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 30 minutes; Blocking buffer (normal goat serum) at 37\u00b0C for 20min; Antibody incubation with AGEs Polyclonal Antibody, Unconjugated (bs-1158R) at 1:200 overnight at 4\u00b0C, followed by a conjugated secondary and DAB staining.$

Paraformaldehyde-fixed, paraffin embedded rat kidney; Antigen retrieval by boiling in sodium citrate buffer (pH6) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 30 minutes; Blocking buffer (normal goat serum) at 37\u00b0C for 20min; Antibody incubation with AGEs Polyclonal Antibody, Unconjugated (bs-1158R) at 1:200 overnight at 4\u00b0C, followed by a conjugated secondary and DAB staining.

MCF7 cells were incubated in 5% BSA blocking buffer for 30 min at room temperature. Cells were then stained with AGEs Antibody(bs-1158R)at 1:100 dilution in blocking buffer and incubated for 30 min at room temperature, washed twice with 2%BSA in PBS, followed by secondary antibody incubation for 40 min at room temperature. Acquisitions of 20,000 events were performed. Cells stained with primary antibody (green), and isotype control (orange).

$Lane 1: Mouse Kidney tissue lysates; Lane 2: Mouse Lung tissue lysates; Lane 3: Mouse Large intestine tissue lysates; Lane 4: Rat Testis tissue lysates ; Lane 5:Rat Lung tissue lysates ; Lane 6: Rat Large intestine tissue lysates; Lane 7: Human U87MG cell lysates probed with AGEs Polyclonal Antibody, Unconjugated (bs-1158R) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.$

Lane 1: Mouse Kidney tissue lysates; Lane 2: Mouse Lung tissue lysates; Lane 3: Mouse Large intestine tissue lysates; Lane 4: Rat Testis tissue lysates ; Lane 5:Rat Lung tissue lysates ; Lane 6: Rat Large intestine tissue lysates; Lane 7: Human U87MG cell lysates probed with AGEs Polyclonal Antibody, Unconjugated (bs-1158R) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.

Applications

WB
ELISA
FCM
IHC-P
IHC-F
IF(IHC-P)
IF(IHC-F)
IF(ICC)

Reactivity

Human
Mouse
Rat

Overview
Catalog #	bs-1158R
Product Name	AGEs Polyclonal Antibody
Applications	WB, ELISA, FCM, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC)
Specificity	Reacts with BSA-AGE.
Reactivity	Human, Mouse, Rat
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	AGEs
Clonality	Polyclonal
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
Target
Gene ID	280717
Swiss Prot	P02769
Subcellular location	Secreted
Synonyms	Advanced Glycation End products; Serum albumin; BSA; ALB
Background	Advanced Glycation End products (AGEs) are the result of a chain of chemical reactions after an initial glycation reaction. The intermediate products are known, variously, as Amadori, Schiff base and Maillard products, named after the researchers who first described them. (The literature is inconsistent in applying these terms. For example, Maillard reaction products are sometimes considered intermediates and sometimes end products.) Side products generated in intermediate steps may be oxidizing agents (such as hydrogen peroxide), or not (such as beta amyloid proteins). "Glycosylation" is sometimes used for "glycation" in the literature, usually as 'non-enzymatic glycosylation. The AGE-modified BSA was produced by reacting BSA with glycolaldehyde under sterile conditions followed by extensive dialysis and purification steps.
Application Dilution
WB	1:300-5000
ELISA	1:500-1000
FCM	1:20-100
IHC-P	1:200-400
IHC-F	1:100-500
IF(IHC-P)	1:50-200
IF(IHC-F)	1:50-200
IF(ICC)	1:50-200